Article Figures & Data
Figures
- Figure 1 EAE Disease on CAR-T Cell Therapy
(A) Experimental timeline. (B) Average EAE clinical score after immunization with rhMOG. Multiple t tests revealed p < 0.05 from days 15–26 between WT vs cyclophosphamide (Cy) + anti-CD19 (aCD19) CAR-T cells and from days 21–28 from between Cy alone vs Cy + aCD19 CAR-T cells. Shown is average ± SD. (C) Cerebellar histology 28 days after EAE induction. WT and cyclophosphamide treated mice show typical perivascular mononuclear inflammatory cell foci in the white matter (indicated by arrows), whereas the Cy treated with aCD19 CAR-T cells or control cells are normal. Bar = 100 µm and applies to all. (D) Representative total numbers of meningeal and parenchymal foci within spinal cord and brain per sacrificed mouse shown, 2 mice per group. aCD20 as anti-CD20, Cy as cyclophosphamide, and aCD19 CAR as anti-CD19 CAR-T cell. CAR = chimeric antigen receptor; Cy = cyclophosphamide; EAE = experimental autoimmune encephalomyelitis; MOG = myelin oligodendrocyte protein; WT = wild type.
- Figure 2 B Cell Depletion Based on Treatment
(A) Frequency of CD45+CD11b-CD19+ cells, average of 5 mice peripheral blood from 5 µL of tail vein blood as ratio against WT. (B) Frequency of CD45+CD11b-CD19+ cells, average of 2 mouse per disease cohort per compartment which included spleen, inguinal lymph node, and femoral bone marrow, and 1 mouse per CNS (brain and spinal cord) on day 17 postimmunization. Shown is average ± SD. (C) Frequency of CD45+CD11b-CD19+ cells, average of 2 mouse per disease cohort per compartment which included spleen, inguinal lymph node, and femoral bone marrow, and CNS (brain and spinal cord) on day 28 postimmunization. Paired t test, p value <0.05 considered significant (*), if p < 0.009 (**). WT = wild type.
- Figure 3 Endogenous T Cell Response Based on Treatment
(A) Frequency of CD45+CD4+IL17+ (Th17) or CD45+CD4+IFNg+ (Th1) cells of 1 mouse per disease cohort from periphery (spleen) or CNS (brain and spinal cord) on day 17 postimmunization. (B) Frequency of CD45+CD4+IL17+ (Th17) or CD45+CD4+IFNg+ (Th1) cells, average of 3 mice per disease cohort from periphery (spleen) or CNS (brain and spinal cord) on day 28 postimmunization (C) Frequency of CD4+CD25+FOXp3+ cells average of 2 mice per disease cohort per compartment on day 28 postimmunization. Shown is average ± SD.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
